Healthcare Industry News: chronic kidney disease
News Release - October 6, 2006
Affymax Appoints Daniel K. Spiegelman to Board of DirectorsPALO ALTO, Calif., Oct. 6 (HSMN NewsFeed) -- Affymax, Inc. a clinical-stage pharmaceutical company, today announced the appointment of Daniel K. Spiegelman to the Company's board of directors. Mr. Spiegelman is currently senior vice president and chief financial officer (CFO) of CV Therapeutics (Nasdaq: CVTX ), a position he has held since 1999.
"Dan Spiegelman has an extensive background in the financial and commercial issues facing growing biotechnology companies, and he is an important addition to Affymax's board. He has helped CV Therapeutics raise more than $1 billion in financing and has overseen its transition from an R&D-focused company into a commercial entity with two approved products and approximately 700 employees," said Arlene M. Morris, president and chief executive officer of Affymax. "His experience will be valuable to Affymax as we advance our lead product candidate Hematide(TM) through clinical development and, if successful, into commercialization for the treatment of anemia in patients with chronic kidney disease and cancer."
Mr. Spiegelman joined CV Therapeutics in January 1998 as vice president and CFO. A publicly traded biopharmaceutical company, CV Therapeutics is focused on applying molecular cardiology to the discovery, development, and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. Previously, he was employed by Genentech, Inc., where he held a number of positions in the treasury department, including treasurer.
Mr. Spiegelman also serves as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. He previously served as a director for Xcyte Therapies, Inc. before its merger with Cyclacel in March 2006.
He holds a B.A. in economics from Stanford University and an M.B.A. from Stanford Graduate School of Business.
About Affymax, Inc.
Affymax, Inc. is a clinical-stage biopharmaceutical company developing novel peptide-based drugs to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide(TM), is currently in Phase 2 clinical trials for the treatment of anemia associated with chronic kidney disease and cancer.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.